Clinical Trials Logo

Clinical Trial Summary

ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. This is a randomized waitlist control trial. The length of time in the trial is 15 weeks and the intervention is 6 weeks long.


Clinical Trial Description

ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. Since the investigator's prior research shows that stronger hostile attributions are associated with poorer perspective taking,39 ICAN employs a unique perspective-positioning technique to train perspective taking and reduce hostile attributions. After recalling a personal situation in which others' ambiguous actions led to an unpleasant outcome, participants will explore different perspectives: sitting or standing in one position, s/he will explore his or her own thoughts and feelings (self-perspective), then move to a different position to experience the other person's perspective, eliciting their thoughts and feelings.

In 40 participants with TBI, we will conduct a Phase I, randomized waitlist controlled trial with 4 data collection points: Baseline; Posttest I (post-treatment for ICAN; post-wait period for WLC); Posttest II (WLC post-treatment). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03648476
Study type Interventional
Source Indiana University
Contact Kelsey Hurm, MS
Phone 3173292044
Email khurm@iu.edu
Status Recruiting
Phase N/A
Start date November 2, 2018
Completion date August 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Recruiting NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Not yet recruiting NCT03559114 - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST) Phase 3
Not yet recruiting NCT03227354 - Validation of Non-invasive Absolute Intracranial Pressure Monitoring N/A
Recruiting NCT02962349 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Active, not recruiting NCT02339220 - The Brave Initiative: Bringing Rehabilitation to American Veterans in an Enriched Environment N/A
Completed NCT02836951 - Rapid Diagnostics for Traumatic Brain Injury (TBI) N/A
Recruiting NCT02613936 - Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury N/A
Recruiting NCT03373331 - Treating Emotional Processing Impairments in Individuals With TBI N/A
Recruiting NCT02465242 - Pupillometry for the Prediction of Neurologic Outcomes in Severe Traumatic Brain Injury N/A
Recruiting NCT02255799 - Multicenter Evaluation of Memory Remediation After TBI With Donepezil Phase 3
Active, not recruiting NCT02424656 - Alterations in the Brain's Connectome After Severe Traumatic Brain Injury
Withdrawn NCT02148367 - Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI Phase 2
Terminated NCT02218216 - TBI MR Study 3 Houston Methodist N/A
Terminated NCT02148783 - Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI Phase 2
Active, not recruiting NCT01618786 - Flooring for Injury Prevention Trial N/A
Active, not recruiting NCT01606111 - The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Phase 4